Teva stock bounded back into a buy zone Tuesday after third-quarter sales decelerated, but still beat Wall Street's expectations.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Teva CEO Explains Why Drugmaker Is Growing Despite Sales Slump ·
Investor's Business Daily
